Kennedy Capital Management Inc. grew its position in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 89.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,807 shares of the biopharmaceutical company’s stock after acquiring an additional 24,027 shares during the quarter. Kennedy Capital Management Inc.’s holdings in Clovis Oncology were worth $3,455,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Capital Analysts LLC bought a new stake in shares of Clovis Oncology during the 3rd quarter worth $111,000. Cypress Capital Management LLC WY raised its stake in shares of Clovis Oncology by 272.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares during the period. Commonwealth Equity Services Inc bought a new stake in shares of Clovis Oncology during the 3rd quarter worth $239,000. First Republic Investment Management Inc. bought a new stake in shares of Clovis Oncology during the 3rd quarter worth $251,000. Finally, BB&T Securities LLC bought a new stake in shares of Clovis Oncology during the 3rd quarter worth $288,000.
In other news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now owns 16,618 shares of the company’s stock, valued at $997,080. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $64.16, for a total value of $192,480.00. Following the transaction, the insider now directly owns 182,583 shares of the company’s stock, valued at approximately $11,714,525.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,500 shares of company stock worth $1,371,210. Company insiders own 12.50% of the company’s stock.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The firm had revenue of $17.04 million for the quarter, compared to analysts’ expectations of $19.42 million. During the same period in the prior year, the business posted ($1.83) earnings per share. The company’s revenue was up 21746.2% on a year-over-year basis. research analysts predict that Clovis Oncology Inc will post -4.75 EPS for the current year.
A number of research firms have recently commented on CLVS. BidaskClub upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 6th. Stifel Nicolaus lowered their target price on Clovis Oncology from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. SunTrust Banks lowered their target price on Clovis Oncology from $95.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Cann reiterated a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, February 27th. Finally, Barclays set a $85.00 target price on Clovis Oncology and gave the stock a “buy” rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $87.84.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3259347/kennedy-capital-management-inc-has-3-46-million-holdings-in-clovis-oncology-inc-clvs.html.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.